US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio Third Quarter Results 2024

Bergen, Norway, November 13, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024, and provided a business update.   Highlights, including post period:   BGBC016 1L NSCLC STK11m Study · Ph1b enrollment completed; acceptable safety and pharmacokinetics announced in September 2024 · The Ph2a portion of the study continues to accrue patients both in the US and in Europe 1L

BerGenBio ASA: Invitation to third quarter 2024 results webcast

Bergen, Norway, 5 November 2024 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2024 on Wednesday 13 November 2024. BerGenBio's senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To participate in the webcast please use this link:   Webcast Q3 2024 

CEO Martin Olin steps down

Bergen, Norway, 10 October 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces today that CEO, Martin Olin will be leaving the company to pursue other opportunities. Martin will remain in his position during a transition period. “On behalf of the Board of Directors, I want to thank him for his work and leadership over the last three years. Martin has since he joined navigated the company through a strategic transition and established a solid platform for the further development

BerGenBio ASA: Minutes from Extraordinary General Meeting

Bergen, Norway,10 October 2024 – An Extraordinary general meeting of BerGenBio ASA was virtually held today 10 October 2024 at 10.00 CEST.   All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 19 September 2024 as further set out in the minutes from the extraordinary general meeting attached hereto and available at https://www.bergenbio.com/investors/general-meetings/.   For further information, please contact:   Martin Olin CEO, BerGenBio ASA ir@bergenbio.com   Rune Skeie CFO, BerGenBio ASA rune.

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

Ph1b data support safety, predictable PK and adequate plasma exposure    Bergen, Norway, October 7, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients.   The Phase 1b part of the study evaluated three escalating doses of BerGenBio’s selective AXL inhibitor bemcentinib in combination with standard chemo-immunotherapy (CIT),

BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Bergen, Norway – 19 September 2024: BerGenBio ASA (OSE:BGBIO) will be holding a Extraordinary General Meeting virtually on 10 October 2024 at 10:00 hours (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company’s website: https://www.bergenbio.com/investors/general-meetings/   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

Bergen, Norway, September 9, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference held in New York City, September 9-11, 2024.    Chief Executive Officer Martin Olin will provide a business update including the ongoing BGBC016 clinical study in 1st line Non-Small Cell Lung Cancer with STK11 mutations.   The presentation used at the conference is available in the

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Bergen, Norway, August 21, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update.   Highlights, including post period:   · BGBC016 1L NSCLC STK11m study continues to progress as planned. Enrollment in the Ph1b part completed. Data Safety Monitoring Board review of data from the final Ph1b dose cohort supports safety and tolerability of the combination of

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

Bergen, Norway, August 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio’s selective AXL inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m). BerGenBio’s on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of

BerGenBio ASA: Registration of share capital reduction

Bergen, 15 August 2024: Reference is made to the stock exchange announcement made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's general meeting resolving a share capital decrease by reducing the nominal value of the Company's shares by NOK 9 from NOK 10 to NOK 1, resulting in a decrease of the Company's share capital by NOK 351,784,044, from NOK 390,871,160 to NOK 39,087,116.   The resolution was announced by the Norwegian Register of Business Enterprises on 28 May 2024, whereafter followed a six-week creditor notice period. The creditor period has been

BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast

Bergen, Norway, 13 August 2024 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2024 on Wednesday 21 August 2024. The briefing will take place at the Conference “Vestland på Børs” at 09:45 am CEST where BerGenBio's senior management team will provide a business update. The presentation will webcast live, a link will be available at www.bergenbio.com in the Investors/Financial Reports section 

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

BerGenBio receives positive recommendation from independent Data and Safety Monitoring Board to initiate second dose in Ph2a of BGBC016 trialBergen, Norway, July 29, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio’s Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also recommended that under the study protocol, no

BerGenBio ASA: Grant of share options

Bergen, Norway, 26 June 2024 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company on 23 May 2024 approved the share option program and authorised the board of directors of the Company to issue up to 3,908,711 share options to the Company’s employees as part of a long-term incentive plan.   Options granted under the share option program will normally

BerGenBio ASA – Registration of reverse share split

Bergen, Norway, 3 June 2024. Reference is made to the stock exchange announcement made by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's annual general meeting resolving a reverse share split of the Company's shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. Following such registration, the share capital of the Company is NOK 390,871,160 divided into 39,087,116 shares, each with a nominal value of NOK 10.   For further information, please contact: Martin Olin, CEO, BerGenBio ASA

BerGenBio ASA - Ex. reverse share split and change of ISIN today

Issuer name: BerGenBio ASAEx. date: 30 May 2024Type of corporate action: Reverse share splitReverse split ratio: One hundred (100) old shares give one (1) new share. New par value per share: NOK 10 New ISIN: NO 001 3251173 New number of shares outstanding: 39,087,116 For further information, please contact: Martin Olin, CEO, BerGenBio ASAir@bergenbio.com Rune Skeie, CFO, BerGenBio ASArune.skeie@bergenbio.com About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential

BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

Bergen, Norway, May 29, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update.   Highlights, including post period: · Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a · Site activation of Ph2a in US and Europe proceeding well · Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

Bergen, Norway, May 28, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company.   The parties will collaborate to study BerGenBio’s selective AXL inhibitor, bemcentinib, in combination with Sobi’

BerGenBio ASA - Key information relating to the reverse share split and change of ISIN

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") on 23 May 2023, regarding the Company's annual general meeting resolving a reverse share split of the Company's shares. Key information related to the reverse share split is set out below: · Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1) new share · Date on which the corporate action was made public: 30 April 2024 · Date of approval: 23 May 2024 (AGM) · Last day including right: 29 May 2024 (trading inclusive right of reverse

BerGenBio ASA: New share capital registered

Bergen, Norway, 28 May 2024: Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 23 May 2024 regarding the Company's annual general meeting resolving to increase the Company's share capital by NOK 3.30 by issuance of 33 new shares, each with a nominal value of NOK 0.10 to ensure that the Company's total number of outstanding shares are divisible by 100 and thereby facilitate for the reverse share split in the Company resolved at the same general meeting. The share capital increases pertaining to the new shares is now registered with the Norwegian

BerGenBio ASA – Minutes from the annual general meeting 2024

Bergen, 23 May 2024: BerGenBio ASA held its annual general meeting today digitally through Lumi AGM. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee, including, but not limited to, approval of the 2023 annual accounts, election of a member to the board of directors, the reverse share split, the share capital reduction and the authorisations to the board of directors. The reverse share split is expected to be completed as soon as possible during the next weeks. Shareholders who want to avoid rounding’s of fraction shares

BerGenBio ASA: Invitation to first quarter 2024 results webcast

Bergen, Norway, 22 May 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will announce its results for the first quarter 2024 on Wednesday 29 May 2024. BerGenBio's senior management team will provide a business update at 10:00 am CET. The presentation will webcast live. To participate in the webcast please use this link:   https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/ 

BerGenBio ASA: Notice of Annual General Meeting

Bergen, Norway – 30 April 2024: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 23 May 2024 at 16:00 hours (CEST).   The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and the notice in addition to other attachments are available on the Company’s website: https://www.bergenbio.com/investors/general-meetings   All shareholders are encouraged to exercise their shareholder rights, either through advance electronically voting through VPS Investor Services, by using

BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023

Bergen, Norway – 30 April 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2023 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS).   The Annual Report for 2023 in pdf and European Single Electronic Format (ESEF) are attached to this release and are also available on BerGenBio ASA's website https://www.bergenbio.com/investors/financial-reports     Contacts:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media